Neuroendocrine Tumours clinical trials

Explore recruiting neuroendocrine tumours clinical trials.

Recruiting neuroendocrine tumours studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Neuroendocrine Tumours trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial)

Netherlands, Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. An open-label, multi-center, randomized phase III trial comparing safety and efficacy of personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOC

Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patients with advanced Neuroendocrine Carcinomas (NEC) refractory or ineligible to platinum-containing chemotherapy

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicentre Surveillance Study to Evaluate the Long-term Safety in Participants who Have Been Previously Treated with 177Lu-IPN01072 in an Ipsen-sponsored Clinical Study

France

Therapeutic use (Phase IV) EU CTIS Study details

"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Poland, Austria, Netherlands, Spain, France, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Neuroendocrine Tumours trials by city

Neuroendocrine Tumours in Toronto Neuroendocrine Tumours in Vancouver Neuroendocrine Tumours in Montreal Neuroendocrine Tumours in Calgary Neuroendocrine Tumours in Edmonton Neuroendocrine Tumours in Ottawa Neuroendocrine Tumours in Winnipeg Neuroendocrine Tumours in Quebec City Neuroendocrine Tumours in Hamilton Neuroendocrine Tumours in Kitchener Neuroendocrine Tumours in London Neuroendocrine Tumours in Halifax Neuroendocrine Tumours in New York Neuroendocrine Tumours in Los Angeles Neuroendocrine Tumours in Chicago Neuroendocrine Tumours in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease